Everything that happened on Day 4️⃣ of #AAD26: buff.ly/xFT4iPB

Great British Railways must mean conditions on the railway go forwards, not backwards.

Our annual conference today committed to work for harmonisation of Ts&Cs, national standard part-time arrangements and no use of AI to undermine jobs. #AAD26

Proud to have @unitetheunion #BrumBinStrike rep Danny Taylor speak at our conference in Birmingham.

The bin strikers are an inspiration – and their dispute has shown us the power of trade unionists standing together. #AAD26

Full details of the third day of #AAD26 here: aslef.org.uk/news/aad-2026-day-3

🚽 #DignityForDrivers
🛤️ Rail freight
🎫 Staff travel
🫶 Carers' leave

Day 3️⃣ of #AAD26 saw moves on a host of big issues affecting the railway.

'When we need support, ASLEF has always been there with our members.'

Thank you @usdawunion.bsky.social General Secretary Joanne Thomas, chair of @labourunionsuk.bsky.social, for addressing our conference and for your solidarity. #AAD26

Catch up on everything that happened on the first day of #AAD26 here: buff.ly/7KRrak7

Labour Deputy Leader @lucympowell.bsky.social says that ASLEF and our fellow trade unions are the party's 'superpower'.

Lucy opened #AAD26, our annual conference.

#AAD26 is officially under way in Birmingham.

Labour Deputy Leader Lucy Powell opened our annual conference by thanking ASLEF members for ‘keeping our country going’.

Over the next 5 days, delegates from across our union will debate and decide ASLEF policy for the next year.

Read more: https://endpoints.news/aad26-biogen-declares-phase-2-lupus-win-for-anti-bdca2-antibody/

#JoinTheSprint
sprintome.com

🌟 Biogen's litifilimab shines in Phase 2 lupus trial, with 14.7% of patients showing improved skin lesions after 24 weeks. A potential game-changer for the company's immunology pipeline! #AAD26

Full coverage: https://endpoints.news/aad26-biogen-declares-phase-2-lupus-win-for-anti-bdca2-antibody/

#JoinTheSprint
sprintome.com

Feed: "Endpoints News"
By: Ayisha Sharma on Saturday, March 28, 2026

Biogen's anti-BDCA2 lupus antibody succeeds in Phase 2, giving the company a much-needed bit of optimism in its autoimmune efforts.
endpoints.news/aad26-biogen...

Sanofi's OX40L drug posts another unimpressive Phase 3 eczema result, deepening doubts.
endpoints.news/aad26-sanofi...

#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure

Check out 6 pivotal atopic dermatitis trials presented at #AAD26 that dermatologists know now: